Bevacizumab, a recombinant humanized monoclonal antibody targeting VEGF, was the first approved therapy targeting the VEGF–VEGFR2 axis for the treatment of cancer and has demonstrated beneficial clinical effects in a variety of tumor types [2, 7, 8]. This evidence concerns the gene VEGFA and neoplasm.